应用DNA科学将重点转向遗传医学、出售资产和削减成本。 Applied DNA Sciences shifts focus to genetic medicines, selling assets and cutting costs.

应用DNA科学已宣布进行战略转变,将重点放在生产遗传药物的基本材料上。 Applied DNA Sciences has announced a strategic shift to focus on producing essential materials for genetic medicines. 该公司计划出售其CLEMT平台,将业务费用减少15%,并保留应用DNA临床实验室,以提供有利可图的药理学检测服务。 The company plans to sell its CertainT platform, reduce operating expenses by 15%, and keep Applied DNA Clinical Labs for its profitable pharmacogenomic testing services. 预计到2025年1月9日,其全球监测方案的制造设施将竣工,可能年收入为400万至1 600万美元。 The completion of its GMP manufacturing facility is expected by January 9, 2025, with potential annual revenue of $4 million to $16 million.